With over 400 million power sufferers, India is likely one of the world’s largest medication markets. However whereas most e-pharmacies chase pace, affordability stays the actual problem. Truemeds took a unique route: serving to sufferers change to lower-cost substitutes, a guess now paying off with new funding at about 4 occasions its earlier valuation.
The six-year-old startup has raised $85 million in a brand new spherical that features $65 million in major and $20 million in secondary funding led by Accel, together with participation from Peak XV Companions. TechCrunch first reported on Accel’s talks to again Truemeds final 12 months. Current traders WestBridge Capital and InfoEdge Ventures, additionally participated.
The contemporary spherical has boosted Truemeds’ valuation to over $400 million, up from the $110 million in its final spherical two years in the past.
Based in 2019, Truemeds entered the market at a time when India’s on-line pharmacy area was already crowded with main gamers providing steep reductions on branded generics. However a few of these firms struggled to maintain early momentum — Prosus Ventures-backed PharmEasy, for example, noticed its valuation drop from a peak of $5.6 billion to beneath $600 million, whereas 1mg was acquired by Tata Digital, a part of the Tata Group. As a substitute of competing head-on, Truemeds’ founders selected to concentrate on a comparatively area of interest section: generic medicines.
“There isn’t a method to educate the consumer you can have extra inexpensive choices should you can’t afford these medicine,” stated Truemeds co-founder Akshat Nayyar (pictured above, left) in an interview. “That’s the place we felt that no one within the worth chain was working in the direction of that, and we will bridge that hole.”
The Mumbai-based outfit recommends generic options to shoppers for the branded medicines they want. This finally helps shoppers lower your expenses, as generic medicine are usually extra inexpensive than their branded variations resulting from price efficiencies of their improvement course of.
Truemeds says its differentiated method has paid off, with income rising over 66% year-over-year to ₹5 billion ($57 million) within the final monetary 12 months. The startup says it retains greater than 50% of its income after 12 months and now serves a mean of 500,000 prospects every month, with a complete of three million prospects thus far. Furthermore, it says it now serves over 20,000 postal codes throughout the nation, with greater than 75% of its prospects coming from tier-2 cities and past.
Techcrunch occasion
San Francisco
|
October 27-29, 2025
Nevertheless, educating prospects about options to their prescribed medicines — and convincing them to change from branded medicine to generics — stays a problem.
“Since you get anchored to your prescribed model’s value, and if you immediately see a cheaper price, you need to know why it’s low,” Nayyar advised TechCrunch.
Rising reductions whereas opponents reduce
Whereas in the present day’s e-pharmacies chase pace over financial savings, the sector’s early playbook was totally different. On-line pharmacies in India used to supply reductions of as much as 25% to draw prospects. However Nayyar stated this dropped to twenty% after which 15% — the brand new common — as most burned money to amass new prospects and pivoted to sooner supply as their fundamental differentiator.
Truemeds has gone in the wrong way, growing its common reductions from 29% to 32% within the final 12 months. For a mean consumer who switches manufacturers on the platform, financial savings attain 47% on their medication, says the corporate.
This comes from Truemeds’ deep procurement relationships with pharma firms, the place the startup makes use of its know-how to present producers higher demand visibility, serving to them plan manufacturing extra effectively for upcoming quarters, he stated.
The startup additionally depends by itself logistics in a few of the main cities it operates in and makes use of low-cost logistics companions for the remainder.
“We consider that our four-hour supply mannequin is greater than ample from a power affected person’s perspective,” stated Nayyar. “You’re in a position to do extra deliberate purchases that means, however we need to do it in essentially the most environment friendly method, and go increasingly reductions to the tip consumer relatively than [focus on] the quickest supply for that matter.”
Subsequent up: AI-powered customization and doorstep diagnostics
As Truemeds must persuade prospects to decide on generics over branded medicines, it goes by deeper consultations with them. It already conducts 10-12 million consultations per 12 months. The startup has developed an algorithm over time that appears at numerous parameters to exactly counsel options to the branded medicine a buyer calls for. It considers nuances similar to whether or not the drugs is sugar-coated whether it is for a younger affected person, the place it’s manufactured, and whether or not the plant is GMP-certified, amongst others. The startup additionally has a chatbot to deal with some consumer queries shortly.
Far more is on the roadmap. The corporate plans to develop an AI-based system that customizes conversations primarily based on prospects’ habits and former interactions with generic options. It’s additionally opening a Bengaluru workplace whereas dedicating a minimum of 20% of its capital to engineering and product improvement.
Past medicines, Truemeds is plotting to enter diagnostics by partnerships with nationwide pathology labs, planning to pilot lab testing companies in some tier-2 cities within the subsequent three to 4 months.
“The first mission stays the identical, which is making healthcare inexpensive for the tip consumer,” the co-founder stated. “It began with medicines. Now that the mannequin is getting established, we’re going to hold scaling that. Concurrently, we additionally need to see if we will do one thing comparable on the diagnostics entrance, the place we may be the bottom price supplier of a minimum of the commonest exams.”
The startup additionally plans to extend its achievement heart rely by 300% — from 19 presently — over the subsequent 12 months, aiming to deepen its presence in present markets.
Earlier than this spherical, Truemeds raised $50 million and nonetheless has 30–35% of that capital within the financial institution, Nayyar stated.
The startup has a workforce of two,800 folks, with 250 primarily based in its Mumbai workplace.
